Eli Lilly and Company (NYSE: LLY) reported that patients with moderately to severely active ulcerative colitis maintained disease clearance for four years when treated with Omvoh (mirikizumab-mrkz), according to data from the LUCENT-3 clinical trial.

The study showed that 63.5% of patients who achieved disease clearance at one year sustained it through four years of continuous treatment. Disease clearance requires simultaneous symptomatic, endoscopic and histologic remission, representing a comprehensive measure of treatment success.

The analysis examined patients who achieved clinical remission with Omvoh at one year in the LUCENT-2 maintenance study and continued treatment in the open-label extension study LUCENT-3. Even under the most stringent measure requiring endoscopic normalization in addition to symptomatic and histologic remission, 61.3% of patients maintained these outcomes through four years.

The LUCENT-3 extension study tracked patients for an additional three years beyond the initial one-year treatment period. During the three-year extension, researchers documented one ulcerative colitis-related hospitalization and zero disease-related surgeries among Omvoh-treated patients.

Of patients completing one year of maintenance therapy who continued to LUCENT-3, 12% reported serious adverse events and 7% discontinued treatment due to adverse events. The safety profile remained consistent with previous data, with no new safety signals observed.

Omvoh is an interleukin-23p19 antagonist approved for treating moderately to severely active ulcerative colitis and Crohn's disease in adults across 47 countries. The drug received regulatory approval in the United States for both conditions, including a single-injection maintenance regimen for ulcerative colitis.

The findings were presented at Digestive Disease Week and represent data from the first interleukin-23p19 inhibitor to demonstrate sustained disease clearance over four years in ulcerative colitis patients, according to the company statement.